HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+0.84%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.5B
AUM Growth
+$2.5B
(-1.2%)
Cap. Flow
+$9.85M
Cap. Flow
% of AUM
0.39%
Top 10 Holdings %
Top 10 Hldgs %
44.4%
Holding
64
New
13
Increased
16
Reduced
20
Closed
13
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$127M |
| 2 |
Zimmer Biomet
ZBH
|
$99.3M |
| 3 |
Baxter International
BAX
|
$90.3M |
| 4 |
Biogen
BIIB
|
$83.1M |
| 5 |
Labcorp
LH
|
$79.5M |
Top Sells
| 1 |
Humana
HUM
|
$147M |
| 2 |
Elanco Animal Health
ELAN
|
$97.3M |
| 3 |
Neurocrine Biosciences
NBIX
|
$79.1M |
| 4 |
AMRN
Amarin Corp
AMRN
|
$59.1M |
| 5 |
Align Technology
ALGN
|
$56.2M |
Sector Composition
| 1 | Healthcare | 95.64% |
| 2 | Technology | 2.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Edwards Lifesciences
EW
$47.8B
| $138M | 5.2% | 625,990 +3,760 | +0.6% | +$827K |
|
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $135M | 5.09% | 1,493,480 -877,910 | -37% | -$79.1M |
|
3
Merck
MRK
$210B
| $131M | 4.96% | 1,558,290 +265,880 | +21% | +$22.4M |
|
|
4
Intuitive Surgical
ISRG
$170B
| $127M | 4.8% | +235,205 | New | +$127M |
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $115M | 4.35% | 679,690 +141,250 | +26% | +$23.9M |
|
|
6
Zimmer Biomet
ZBH
$21B
| $99.3M | 3.75% | +723,370 | New | +$99.3M |
|
7
Danaher
DHR
$147B
| $99.2M | 3.75% | 686,980 +179,140 | +35% | +$25.9M |
|
|
8
Baxter International
BAX
$12.7B
| $90.3M | 3.41% | +1,032,820 | New | +$90.3M |
|
9
Madrigal Pharmaceuticals
MDGL
$9.76B
| $88.9M | 3.36% | 1,031,220 -1,050 | -0.1% | -$90.5K |
|
10
UnitedHealth
UNH
$281B
| $85.5M | 3.23% | 393,530 -3,910 | -1% | -$850K |
|
|
CVRS
11
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $85.5M | 3.23% | 19,981,655 | – | – |
|
|
12
Biogen
BIIB
$19.4B
| $83.1M | 3.14% | +356,860 | New | +$83.1M |
|
|
NVRO
13
DELISTED
NEVRO CORP.
NVRO
| $82M | 3.1% | 953,820 -273,910 | -22% | -$23.5M |
|
|
14
Labcorp
LH
$23.1B
| $79.5M | 3.01% | +473,480 | New | +$79.5M |
|
|
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $71.6M | 2.71% | 2,628,840 -164,830 | -6% | -$4.49M |
|
16
Abbott
ABT
$231B
| $63.3M | 2.39% | 756,400 -387,760 | -34% | -$32.4M |
|
17
Medtronic
MDT
$119B
| $58.1M | 2.2% | 534,750 -43,550 | -8% | -$4.73M |
|
18
Bristol-Myers Squibb
BMY
$96B
| $56.7M | 2.14% | 1,117,710 -894,940 | -44% | -$45.4M |
|
|
CHNG
19
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $51.4M | 1.94% | 4,254,430 +1,564,240 | +58% | +$18.9M |
|
20
HCA Healthcare
HCA
$94.5B
| $49M | 1.85% | 407,230 -12,100 | -3% | -$1.46M |
|
21
Charles River Laboratories
CRL
$8.04B
| $48.4M | 1.83% | 365,360 +947 | +0.3% | +$125K |
|
|
BLUE
22
DELISTED
bluebird bio
BLUE
| $46.6M | 1.76% | 507,090 +139,000 | +38% | +$12.8M |
|
|
BPMC
23
DELISTED
Blueprint Medicines
BPMC
| $44.8M | 1.69% | 609,417 +226,913 | +59% | +$16.7M |
|
24
Johnson & Johnson
JNJ
$427B
| $44.4M | 1.68% | +343,540 | New | +$44.4M |
|
|
XENT
25
DELISTED
Intersect ENT, Inc
XENT
| $43.2M | 1.63% | 2,541,630 -234,265 | -8% | -$3.98M |
|